Key result
Serum digoxin concentration-guided therapy was associated with increased all-cause mortality compared to nonusers in HFrEF patients.
Why the study?
Recent studies suggested digoxin may increase mortality in HFrEF, but previous trials largely did not measure serum digoxin concentration or guide therapy by it.
Does serum concentration-guided digoxin therapy affect all-cause mortality in patients with HFrEF?
Cohort (n=580)
Does serum concentration-guided digoxin therapy affect all-cause mortality in patients with HFrEF?
Serum concentration-guided digoxin therapy is associated with increased all-cause mortality in optimally treated HFrEF patients, particularly when serum concentrations reach or exceed 0.9 ng/mL.
Answers are grounded in this paper and cite their sources.
May warrant caution with digoxin in HFrEF; leaves open confirmation of mortality risk in randomized trials.
BACKGROUND: Recently published studies suggested that digoxin may increase mortality in heart failure with reduced ejection fraction (HFrEF). However, in the vast majority of former trials serum digoxin concentration (SDC) was not measured and therapy was not SDC-guided. AIM: To assess the impact of SDC-guided digoxin therapy on mortality in HFrEF patients. METHODS: Data of 580 HFrEF patients were retrospectively analyzed. In patients on digoxin, SDC was measured every 3 months and digoxin dosage was SDC-guided (target SDC: 0.5-0.9 ng/mL). All-cause mortality of digoxin users and nonusers was compared after propensity score matching (PSM). RESULTS: After 7.1 ± 4.7 years follow-up period (FUP) all-cause mortality of digoxin users (n = 180) was significantly higher than nonusers (n = 297) (propensity-adjusted HR = 1.430; 95% CI = 1.134-1.804; P = .003). Patients having SDC of 0.9 to 1.1 ng/mL (n = 60) or > 1.1 ng/mL (n = 44) at any time during the FUP had an increased risk of all-cause mortality (HR = 1.750; 95% CI = 1.257-2.436, P = .001 and HR = 1.687; 95% CI = 1.153-2.466, P = .007), while patients having a maximal SDC < 0.9 ng/mL (n = 76) had similar mortality risk (HR = 1.139; 95% CI = 0.827-1.570, P = .426), compared to digoxin nonusers. CONCLUSIONS: According to our propensity-matched analysis, SDC-guided digoxin therapy was associated with increased all-cause mortality in optimally treated HFrEF patients, especially with SDC ≥0.9 ng/mL. These results reinforce the expert opinion that digoxin in HFrEF can only be used among carefully selected patients with close SDC monitoring.
No takes yet. Share an insight, caveat, or question.
Muk et al. (2020) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=580). Serum digoxin concentration-guided digoxin therapy vs. Digoxin nonusers was evaluated on All-cause mortality (HR 1.430, 95% CI 1.134-1.804, p=.003). Serum digoxin concentration-guided therapy was associated with increased all-cause mortality compared to nonusers in HFrEF patients.
Synapse has enriched 10 related papers. Consider them for comparative context: